NABP Pharmacy Accreditation FAQ — Your Questions Answered
Cost statements revised October 2026.
NABP publishes standards and process guides. This FAQ answers the operational questions pharmacy operators and distributors ask, drawing on NABP published data, regulatory filings, and IHS consulting work.
What Is NABP Accreditation?
What is NABP and what pharmacy accreditation programs does it administer?
The National Association of Boards of Pharmacy (NABP) is a nonprofit organization that assists state boards of pharmacy in protecting public health by providing programs and services to the regulatory community. NABP is not a standards development organization in the same vein as URAC or The Joint Commission — it functions primarily as a regulatory enforcement and verification body on behalf of state licensing authorities.
NABP administers four primary accreditation and verification programs relevant to pharmacies and drug distributors:
- Drug Distributor Accreditation (DDA) — formerly VAWD. For wholesale prescription drug distributors. Some states require NABP accreditation for a license; check each state.
- Specialty Pharmacy Accreditation — for dispensing pharmacies serving patients with complex chronic conditions.
- Digital Pharmacy Accreditation — formerly VIPPS. For internet and mail-order pharmacies.
- Healthcare Merchant Accreditation — which NABP describes as available to a wide range of health care and health care-adjacent business models; NABP says merchants typically use it to meet requirements set by online advertising platforms and card brand networks.
What is NABP Drug Distributor Accreditation (DDA) and who needs it?
NABP Drug Distributor Accreditation — formerly called VAWD (Verified-Accredited Wholesale Distributors) — verifies that wholesale prescription drug distributors comply with federal law, state regulations, Good Distribution Practices, and Drug Supply Chain Security Act (DSCSA) requirements. NABP's Drug Distributor page says that in some states it may be necessary to possess NABP accreditation to obtain a license, and tells distributors to inquire with each state in which the facility does business.
What is the difference between VAWD and DDA?
VAWD and DDA are the same program — NABP renamed VAWD (Verified-Accredited Wholesale Distributors) to DDA (Drug Distributor Accreditation) to better reflect the program's scope and scope of eligible applicants. The accreditation criteria, two-phase inspection process, and underlying standards are substantively unchanged. If you encounter either term in state regulations or PBM contracts, they refer to the same NABP program.
What is Digital Pharmacy Accreditation (formerly VIPPS) and who needs it?
NABP Digital Pharmacy Accreditation — formerly VIPPS (Verified Internet Pharmacy Practice Sites) — is the accreditation program for internet-based and mail-order pharmacies that dispense prescriptions to patients online. NABP's 2019 report on online opioid sales states that NABP research has consistently shown that 95-96% of websites selling prescription-only drugs are doing so illegally. The IQVIA Institute reported in 2023 that it identified 19,013 illegal online pharmacies as of March 2023 and estimated that they provided 416 million prescriptions to patients between January 2017 and December 2022.
Sources: NABP, The Online Sale of Opioids Continues to Put Lives at Risk (2019); IQVIA Institute, 2023
What is the .Pharmacy domain verification program?
The .pharmacy top-level domain is controlled by NABP as a trust indicator for legitimate online pharmacies. The domain itself is bought through an NABP-authorized registrar, which sets the fee; NABP's cost FAQ lists it separately from NABP's own program fees. The .pharmacy domain is a separate NABP verification from Healthcare Merchant Accreditation, but NABP's Healthcare Merchant cost FAQ calls the .pharmacy domain name fee required for that program, so a pharmacy pursuing Healthcare Merchant Accreditation should plan for the domain.
Who Needs NABP Accreditation?
What types of organizations can apply for NABP DDA?
NABP DDA eligibility extends well beyond traditional wholesale distributors. Eligible organization types include: wholesale drug distributors; Third-Party Logistics Providers (3PLs) that take physical possession of prescription drugs; virtual manufacturers holding drug application rights but using contract manufacturing; Section 503B outsourcing compounding facilities; reverse distributors handling expired drug destruction; and import/export entities. Each nontraditional entity type has specific eligibility pathways and documentation requirements not addressed in NABP's standard applicant guidance. IHS helps you prepare your eligibility questions and maps the applicable standards before you invest resources in the application process.
Are compounding pharmacies eligible for NABP DDA or specialty pharmacy accreditation?
Section 503B outsourcing facilities — facilities that compound sterile medications for office use without patient-specific prescriptions — are explicitly eligible for NABP DDA. Traditional 503A compounding pharmacies (patient-specific prescriptions) have specific pathways depending on whether they also engage in wholesale distribution activity. All compounding facilities subject to NABP review must comply with revised USP Chapters 795 (nonsterile) and 797 (sterile), which NABP says became effective on November 1, 2023. These revisions require a designated person for USP compounding oversight; NABP reports that 21% of nonsterile and 13% of sterile facilities inspected under its Verified Pharmacy Program in the first 10 months afterward were unaware of the requirement or had not yet assigned someone to the role. Source: NABP Verified Pharmacy Program Data, 2024
Do California pharmacies need additional compliance beyond NABP accreditation?
Possibly. NABP accreditation does not replace state licensure. A pharmacy that ships prescriptions into a state should check that state board of pharmacy's rules for nonresident pharmacies, including any requirement for a pharmacist-in-charge licensed in that state, before it ships.
Does North Carolina law affect NABP accreditation requirements for PBM networks?
North Carolina HB 163 (2025) passed the House on April 29, 2025 and was referred to the Senate Committee on Rules and Operations on April 30, 2025; it is not law (NC General Assembly bill page). The House-passed version would bar a pharmacy benefits manager from requiring multiple specialty pharmacy accreditations as a prerequisite for participation in a retail pharmacy network that dispenses specialty drugs. It says the accreditation may be issued by URAC, ACHC, the Joint Commission, "their successors, or any similar nationally recognized accrediting organization." It does not name NABP. Source: NC General Assembly, HB 163 House-passed text (H163v3)
How Does the NABP Accreditation Process Work?
What are the steps to get NABP Drug Distributor Accreditation (DDA)?
IHS prepares clients for NABP DDA in eight steps; one of them, an optional mock survey, is IHS's step, not NABP's: (1) Submit the application in NABP's e-Profile system; (2) complete NABP's Policy and Procedure (P&P) assessment and revise your SOP manuals (many applicants use outside help; IHS does this work); (3) Submit P&P documentation for NABP desk review; (4) Iterative revision and resubmission until written protocols satisfy NABP's reviewer; (5) Optional mock survey (an IHS step) — simulated facility tour, process review, HR file audit, staff interviews; (6) Phase 1 Supply Chain Inspection (SCI) — announced, on-site NABP visit; followed by Phase 2 DDA application processing; (7) Post-survey corrective action plan for any cited deficiencies; (8) Three-year accreditation awarded. Annual compliance reviews in years two and three.
What is the Supply Chain Inspection (SCI) and how does it differ from DDA?
On NABP's Drug Distributor pricing pages, the Supply Chain Inspection is a prerequisite to Drug Distributor Accreditation. SCI has its own application and inspection fees. An applicant seeking Drug Distributor Accreditation also pays NABP's $1,400 eligibility review fee, which NABP lists on its Supply Chain Inspection page and counts in its Drug Distributor three-year total (published by NABP; verify current fees with NABP). SCI covers facility conditions, storage and handling protocols, temperature and humidity monitoring continuity, DSCSA documentation, DEA controlled substance records, and carrier vetting procedures. DDA (Phase 2) is the formal accreditation, with its own application fee and annual maintenance fee; see nabp.pharmacy for the current amounts.
How long does the NABP DDA accreditation process take from application to award?
Plan for 6 to 9 months from initial consulting engagement to final accreditation award. Factors that shorten the timeline: mature existing SOPs, current DSCSA systems, and organized HR files. Factors that extend it: documentation gaps requiring SOP authoring from scratch, multi-facility complexity, or a corrective action cycle following the on-site inspection. The three-year accreditation term requires annual compliance reviews in years two and three, each with a $440 annual participation fee on NABP's current Drug Distributor schedule (published by NABP; verify current fees with NABP).
Can a consultant represent an applicant during the NABP application process?
Consultants assist extensively throughout the NABP process — but the pharmacy or distributor submits all materials directly via its own NABP e-Profile account. IHS prepares all documentation, authors SOPs, coaches staff for surveyor interviews, executes mock surveys, and manages corrective action cycles. IHS does not submit applications on behalf of clients or interact directly with NABP surveyors during the official inspection — the client's staff interfaces with NABP directly. This is an important distinction: the accreditation is awarded to your organization, not your consultant.
What documentation is required for the NABP DDA application?
NABP's Drug Distributor Accreditation page lists its criteria as Licensure; Facility; Virtual Manufacturers and Wholesale Distributors; Personnel; Record Keeping; Authentication and Verification; Returned, Damaged, and Outdated Drugs; Policies and Procedures; and Nontraditional Business Models (NABP, Drug Distributor Accreditation, page opened October 20, 2026).
How Much Does NABP Accreditation Cost?
How much does NABP DDA accreditation cost?
On NABP's Drug Distributor pricing pages, the Supply Chain Inspection (SCI) is a prerequisite and is priced separately: a $2,200 application fee plus a $4,300 inspection fee ($6,500) for most business models, or $2,200 plus $8,300 ($10,500) for outsourcing facilities. The DDA itself adds a $1,400 eligibility review fee, a $3,280 application fee and a $440 annual participation fee in each of years one to three. Adding NABP's $6,500 Supply Chain Inspection total for most business models to NABP's $6,000 three-year Drug Distributor total gives $12,500. NABP does not publish that combined figure; it is IHS's sum of NABP's published lines. NABP says program fees are subject to change and that additional fees can apply, for example for time extensions, protracted policy and procedure reviews or inspection remediation. NABP also offers expedited processing for an additional fee if its staffing allows. NABP's pages say it is adjusting pricing effective January 4, 2027, and that to apply under current pricing an application and payment must be submitted on or before December 31, 2026. Published by NABP; verify current fees with NABP. IHS consulting fees are scoped per engagement — contact us for a tailored proposal. Sources: NABP, Drug Distributor pricing and NABP, Supply Chain Inspection pricing.
Is NABP changing its Drug Distributor Accreditation fees in 2027?
NABP's Drug Distributor and Supply Chain Inspection pricing pages say that effective January 4, 2027, NABP is adjusting pricing for the programs listed on them, and that to apply under current pricing an application and payment must be submitted on or before December 31, 2026. Those pages do not publish the new amounts. Check NABP's pricing pages or your NABP e-Profile for the new schedule before you plan a budget. Published by NABP; verify current fees with NABP.
What are the total costs of NABP accreditation including consulting?
NABP DDA fees are set by NABP and cover a multi-year cycle; see nabp.pharmacy for the current schedule. For specialty pharmacy accreditation fees, NABP's current schedule is available at nabp.pharmacy. IHS consulting engagements are scoped to each client's specific situation. IHS begins every engagement with a complimentary discovery call that produces a fixed-fee proposal tailored to your organization's size, documentation maturity, and timeline. Contact us to schedule.
What Can Go Wrong? Deficiencies and Risk
Which areas can lead to findings in an NABP specialty pharmacy survey?
Areas that can lead to NABP specialty pharmacy survey findings include: (1) Incomplete patient profiles (PHY.F) — missing diagnosis codes, full medication histories including OTC and herbal supplements, allergies, and therapeutic goals; (2) Narrow DUR systems (PHY.E) — automated systems configured to check only the first two medications in a patient profile rather than cross-referencing against all current health conditions; (3) Missing patient education documentation (PHY.F) — no written proof that a pharmacist verbally educated the patient on safe handling and vaccine recommendations; (4) Welcome kit tracking failures (PHY.F) — no verifiable documentation that required informational welcome kits were sent and received; (5) HR competency assessment gaps (ACC.D) — personnel files lacking initial training documentation or ongoing competency evaluations.
Which areas can lead to NABP DDA survey findings?
For wholesale distributors, areas that can lead to DDA findings include: (1) Poorly authored SOPs (ACC.H) — outdated, internally conflicting, or staff-inaccessible SOP manuals; (2) Temperature and humidity monitoring gaps (ACC.F) — missing continuous 24/7/365 electronic warehouse monitoring or absent initial thermal mapping; (3) Carrier vetting failures (ACC.F) — inability to document that contracted shipping carriers conduct mandatory criminal background checks and random toxicology screenings on employees handling prescription assets.
What happens if a pharmacy fails the NABP on-site survey?
A failed NABP survey produces a post-survey letter citing specific operational and documentary deficiencies under the applicable standard sections. NABP does not publish pass or denial rates. The corrective action cycle adds weeks to months to the accreditation timeline depending on the nature and number of deficiencies. IHS provides post-survey corrective action plan authoring and remediation management to resolve findings as quickly as possible. An IHS mock survey before the official NABP visit gives the organization time to address gaps before the surveyor arrives.
What DSCSA documentation must a wholesale distributor provide during NABP review?
NABP lists the criteria for Drug Distributor Accreditation, including Record Keeping, on its Drug Distributor Accreditation page. Check those criteria for the documentation NABP reviews, and confirm with NABP what DSCSA documentation it expects.
How Does NABP Compare to Alternatives?
How does NABP specialty pharmacy accreditation compare to URAC specialty pharmacy accreditation?
NABP and URAC represent different accreditation philosophies built for different organizational needs. NABP operates as a regulatory enforcement body — its specialty pharmacy standards center on drug supply chain integrity, licensure verification, dispensing accuracy, and operational compliance with state and federal law. URAC's specialty pharmacy accreditation emphasizes clinical quality management, patient outcomes measurement, care coordination, and health plan integration.
In PBM network terms, which accreditation a PBM network asks for is set in each PBM's contract; check the contract. For a full side-by-side analysis — including cost, timeline, standards scope, and which to pursue first — see our NABP vs. URAC comparison page.
Sources: PharmaTimes; Pharmacy Times
Which PBMs or payers require or prefer NABP vs. URAC accreditation?
Which accreditation a PBM network asks for is set in each PBM's contract; check the contract. Other major PBM network requirements vary by contract tier and must be verified against your specific agreements. North Carolina HB 163 (2025) passed the House on April 29, 2025 and was referred to the Senate Committee on Rules and Operations on April 30, 2025; it is not law (NC General Assembly bill page). The House-passed version would bar a pharmacy benefits manager from requiring multiple specialty pharmacy accreditations as a prerequisite for participation in a retail pharmacy network that dispenses specialty drugs. It says the accreditation may be issued by URAC, ACHC, the Joint Commission, "their successors, or any similar nationally recognized accrediting organization." It does not name NABP. IHS reviews your specific PBM contracts as part of every accreditation strategy engagement to identify which accreditation satisfies each network requirement. Source: NABP blog
Can a pharmacy hold both NABP and URAC accreditation simultaneously?
Yes. Pharmacies with diversified PBM contracts may consider dual accreditation. NABP and URAC standards overlap in several operational areas, which means a well-structured dual-accreditation engagement uses shared documentation rather than creating entirely separate compliance systems. IHS advises on documentation architecture and sequencing for pharmacies pursuing both programs.
Have a Question Not Answered Here?
IHS is an accreditation consulting firm. Thomas G. Goddard, JD, PhD (former URAC COO and General Counsel) personally leads IHS's NABP engagements. IHS advises on NABP, URAC and ACHC programs. For The Joint Commission, IHS offers readiness for Home Care pharmacy accreditation and Health Care Staffing Services certification. If your question is about which program you need, what it will cost, or how to structure your accreditation strategy, we can answer it in a no-obligation gap analysis call.
Cost statements revised October 2026.
